NEUE · As filed with the SEC

NeueHealth balance sheet, by quarter

The statement as NeueHealth presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Condensed Consolidated Balance Sheets · USD thousands

USD thousands	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024
Assets
Current assets:
Cash and cash equivalents	131,618	138,101	83,295	109,839
Short-term investments	13,946	7,004	9,871	8,842
Accounts receivable, net of allowance of $55 and $27, respectively	53,074	41,716	36,594	43,078
ACO REACH performance year receivable	—	—	95,075	—
ACO REACH performance year receivable	321,596	468,346	—	261,215
Current assets of discontinued operations	89,804	94,467	173,006	127,638
Current assets of held-for-sale operations (Note 15)	—	—	—	6,108
Discontinued Operations	—	—	173,006	—
Prepaids and other current assets	29,844	38,572	36,807	32,712
Total current assets	639,882	788,206	434,648	589,432
Other assets:
Property, equipment and capitalized software, net	11,664	11,108	11,240	11,677
Intangible assets, net	66,088	68,576	71,064	73,552
Other non-current assets	26,055	27,790	27,431	22,122
Total other assets	103,807	107,474	109,735	107,351
Total assets	743,689	895,680	544,383	696,783
Liabilities, Redeemable Noncontrolling Interest, Redeemable Preferred Stock and Shareholders’ Equity (Deficit)
Current liabilities:
Medical costs payable	97,837	113,850	124,360	123,665
Accounts payable	5,317	5,451	6,298	5,898
Short-term borrowings	1,000	1,000	2,000	0
ACO REACH performance year obligation	248,465	382,478	—	161,855
Discontinued Operations	333,799	335,181	344,651	339,576
Disposal Group, Held-for-Sale, Not Discontinued Operations	—	—	—	4,976
Risk share payable to deconsolidated entity	—	—	123,981	—
Warrant liability	—	—	29,738	—
Risk share payable to deconsolidated entity	123,981	123,981	—	123,981
Warrant liability	27,651	27,089	—	22,252
Other current liabilities	70,362	75,022	79,200	90,235
Total current liabilities	908,412	1,064,052	710,228	872,438
Long-term borrowings	—	—	—	120,252
Total long-term borrowings	212,433	207,400	202,614	—
Other liabilities	15,899	17,200	17,649	16,616
Total liabilities	1,136,744	1,288,652	930,491	1,009,306
Redeemable noncontrolling interests	55,729	47,769	48,580	117,876
Redeemable Series A and B preferred stock	920,417	920,417	920,417	920,417
Redeemable Series A preferred stock	747,481	747,481	747,481	747,481
Redeemable Series B preferred stock	172,936	172,936	172,936	172,936
Shareholders’ equity (deficit):
Common stock, $0.0001 par value; $3,000,000,000 shares authorized in 2025 and 2024; $9,024,240 and $8,320,959 shares issued and outstanding in 2025 and 2024, respectively	1	1	1	1
Additional paid-in capital	3,107,121	3,105,109	3,099,423	3,100,990
Accumulated deficit	(4,464,323)	(4,454,268)	(4,442,529)	(4,439,807)
Accumulated other comprehensive loss	0	0	0	0
Treasury Stock, at cost, $31,526 shares at June 30, 2025, and December 31, 2024, respectively	(12,000)	(12,000)	(12,000)	(12,000)
Total shareholders’ equity (deficit)	(1,369,201)	(1,361,158)	(1,355,105)	(1,350,816)
Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders’ equity (deficit)	743,689	895,680	544,383	696,783

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.